PROBLEM RELEVANCE

Recent years, the possibilities of antiadhesive therapy which can block the interaction of bacterial adhesins and receptors of skin cells in order to prevent infection have been actively studied.

OBJECTIVE

To study the efficacy of using a hydrogel containing a 2QR complex and capable of preventing the adhesion of pathogenic microorganisms to the skin in the treatment of patients with allergic contact dermatitis, eczema and atopic dermatitis.

MATERIAL AND METHODS

The study included 100 patients aged 18 to 60 years. Patients of the 1^st group (n=34) used the topical corticosteroid betamethasone dipropionate as monotherapy, patients of the 2^nd group (n=33) — a hydrogel containing a 2QR-complex, patients of the 3^rd group (n=33) — their combination. Evaluation of treatment effectiveness was carried out on the 3^rd, 7^th and 14^th days of therapy.

RESULTS

The total lesion area before treatment in patients of the 1^st group was 30.5%, the 2^nd group — 34.5%, the 3^rd group — 41.5%, on the 14^th day of therapy — 2, 7.5 and 1.5% respectively. Hyperemia and edema in the affected area after 14 days of therapy persisted in 23.5% of patients in group 1, in 45.5% of patients in group 2 and in 6.1% of patients in group 3, oozing and crusts — in 5.9, 45.5 and 3.0%, respectively, lichenification and/or desquamation — in 6.1 and 3.0% of patients in 2^nd and 3^rd groups, dryness and/or cracks — in 11.8 and 15.2% of patients in 1^st and 2^nd groups. The severity of itching/pain and sleep disturbances which averaged 4.6 points in group 1, 4.0 points in group 2 and 4.8 points in group 3 before treatment; after 14 days it was decreased to 0, 2, 0.9 and 0.03 points, respectively.

CONCLUSION

Monotherapy with a hydrogel containing a 2QR complex had a therapeutic effect in more than half of the observed patients. The combined use of the topical corticosteroid betamethasone dipropionate and hydrogel significantly increased the effectiveness of treatment.